Stocks › MRNA
Moderna, Inc.
MRNA·Nasdaq·
United States·USD
United States·USD$187.46
-15.75 (-7.75%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
MRNA
Moderna, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MRNAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of MRNA by members of U.S. Congress · 67 on record · 5 in the last 12 months
Whale Activity
Position changes in MRNA reported for 2026-06-30 by 17 tracked institutional filers
- Increased2
- New0
- Held0
- Decreased6
- Closed2
- No prior filing7
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 30.6M | $2.14B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 23.2M | $1.63B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.6M | $1.09B | decreased |
| Theleme Partners LLP | 8.1M | $564.3M | — |
| TWO SIGMA INVESTMENTS, LP | 7.2M | $503.8M | decreased |
| Step Capital Management Pte. Ltd. | 695.0K | $48.7M | — |
| MILLENNIUM MANAGEMENT LLC | 438.6K | $30.7M | decreased |
| CITADEL ADVISORS LLC | 294.5K | $20.6M | decreased |
| Casdin Capital, LLC | 75.0K | $5.3M | — |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 32.5K | $2.3M | — |
| D. E. Shaw & Co., Inc. | 25.0K | $1.7M | decreased |
| Bridgewater Associates, LP | 11.5K | $807K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by MRNA insiders, by quarter · Form 4
Recent Insider Transactions
3,992 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Hoge StephenPresident | Sale | −40.3K | $146.07 | $5.9M | Sep 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −40.3K | $144.13 | $5.8M | Sep 14, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Sale | −19.8K | $134.49 | $2.7M | Sep 10, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Sale | −15.0K | $134.49 | $2.0M | Sep 10, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Sale | −3,471 | $139.95 | $486K | Sep 1, 2026 | Form 4 ↗ |
| Bancel StephaneChief Executive Officer · Director | Sale | −39.9K | $58.12 | $2.3M | Aug 5, 2026 | Form 4 ↗ |
| Bancel StephaneChief Executive Officer · Director | Sale | −187.0K | $58.79 | $11.0M | Aug 5, 2026 | Form 4 ↗ |
| Bancel StephaneChief Executive Officer · Director | Sale | −147.5K | $56.21 | $8.3M | Aug 5, 2026 | Form 4 ↗ |
| Bancel StephaneChief Executive Officer · Director | Sale | −124.8K | $56.96 | $7.1M | Aug 5, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −53.3K | $67.60 | $3.6M | Jul 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Sale | −53.3K | $51.37 | $2.7M | Jun 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Option exercise | +16.1K | $19.15 | $309K | Jun 15, 2026 | Form 4 ↗ |
| Hoge StephenPresident | Option exercise | +37.2K | $19.15 | $713K | Jun 15, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,705 | $51.59 | $294K | Jun 5, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Option exercise | +11.8K | — | — | Jun 5, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Tax withholding | −5,705 | $51.59 | $294K | Jun 5, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Option exercise | +11.8K | — | — | Jun 5, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Sale | −3,471 | $50.00 | $174K | Jun 4, 2026 | Form 4 ↗ |
| Klinger Shannon ThymeChief Legal Officer | Option exercise | +3,471 | $30.96 | $107K | Jun 4, 2026 | Form 4 ↗ |
| Mock James MChief Financial Officer | Tax withholding | −1,197 | $47.19 | $56K | Jun 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding MRNA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 11.3M | $793.6M | 0.03% | Jun 30, 2026 |
| Growth Fund of America | 14.5M | $684.3M | 0.19% | May 31, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 9.2M | $641.1M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 8.2M | $573.6M | 0.30% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $363.3M | 0.54% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 4.9M | $340.1M | 0.04% | Jun 30, 2026 |
| Growth Fund AMERICAN FUNDS INSURANCE SERIES | 4.6M | $323.6M | 0.57% | Jun 30, 2026 |
| Fidelity Contrafund | 4.3M | $303.6M | 0.17% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 4.3M | $299.7M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 6.2M | $292.9M | 0.30% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list MRNA's shares (CUSIP 60770K107), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Capital World InvestorsSCHEDULE 13G · passive (13G) · 22.3M shares5.6%
Aug 12, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 51.8M shares13.1%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 51.8M shares13.1%
Aug 6, 2026 · ↗ - BAILLIE GIFFORD & COSCHEDULE 13G/A · passive (13G) · 18.2M shares4.6%
Jul 24, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 25.9M shares6.5%
Apr 30, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming moderna as client
Government Contracts
Federal awards to Moderna, Inc. · USAspending
No federal contract awards found for Moderna, Inc..
U.S. Patents
Recent USPTO applications naming Moderna, Inc.
No USPTO patent applications found for Moderna, Inc..
Annual Financials
From MRNA's 10-K filings · XBRL
No annual XBRL figures on record for MRNA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in MRNA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equitySep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 31, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 8, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteMay 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 1, 2026
EDGAR ↗
About Moderna, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001682852 ↗
Former namesModerna Therapeutics, Inc.